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Haptoglobin,
the Good and the Bad
Is it Evidence Based?*
Robert Roberts, MD
Ottawa, Ontario, Canada
Haptoglobin (Hp) is a molecule that circulates in the blood,
to which most of us, particularly cardiologists, pay very little
attention. Nevertheless, it has been the focus of considerable
controversy in past decades as to whether it contributes to
coronary artery disease (CAD) and, in particular, the
formation of coronary atherosclerosis (1,2).
See page 728
Hp, synthesized in the liver, is a sialoglycoprotein found
in the alpha-1 globulin fraction of serum with hemoglobin
(Hb)-binding capacity, and its main physiological function
is to dispose of free-Hb released from the red blood cells
into the plasma. Hp is a positive acute-phase protein
induced by cytokines such as interleukin-6. Hp forms a
strong, noncovalent 1:1 complex with Hb, which is disposed
of in the liver (3). Hb is consistently being released from red
blood cells, as they reach the end of their lifespan, which
averages 90 days. There is adequate Hp in the blood to bind
3 g of Hb, which under normal circumstances prevents
free-Hb from circulating in the blood. Hp evolved as a very
important protective mechanism to prevent the deleterious
effects associated with circulating free-Hb (2).
Free-Hb stimulates lipid peroxidation (3) and is associ-
ated with immune and inflammatory responses, which can
lead to significant tissue injury (2). Free-Hb, as occurs in
rhabdomyolysis, can be associated with renal damage be-
cause it flows through the glomeruli. This is prevented by
the complex of Hp–Hb because it is too large to be filtered
in the kidney and instead is transported to the liver for
appropriate disposal.
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#MOP82810; Canada Foundation for Innovation #11966.The Hp gene is located on chromosome 16, on the long
(q) arm, at band 22.2 (16q22.2), and the gene has 2 forms
(alleles) referred to as Hp1 and Hp2. These alleles give rise
to 3 phenotypes: individuals homozygous for Hp1 (Hp1-1);
heterozygous for Hp (Hp2-1); or homozygous for Hp2
(Hp2-2). The protein consists of 2 chains,  and , with the
 chain having a much higher molecular weight than the 
chain. The gene (Hp1) that encodes for the  chain is
dentical in all species, as is the protein. The Hp2 allele,
hich is specific for humans, encodes for an  chain of high
olecular weight and has 1,700 additional base pairs (2).
he Hp protein encoded by the Hp2 allele binds less Hb
han that of Hp1 and is less efficient in both preventing
xidation and in promoting the uptake of the Hp–Hb
omplex by the CD163 receptor on monocytes (4,5). The
requency of these alleles in the white population is estimated
t 15% for Hp1-1, 50% for Hp2-1, and 35% for Hp2-2.
The relationship between Hp and coronary heart disease
CHD) is believed to be mediated through atherosclerosis.
here are several mechanisms through which Hp may influ-
nce atherosclerosis; a decrease in Hp binding to Hb can lead
o increased lipid peroxidation with immune and inflammatory
esponses. The Hp–Hb complex binds to a receptor (CD163)
n monocytes and macrophages (2), culprits involved in the
athogenesis of atherosclerosis. Lastly, Hp is also known to
orm a complex with apolipoprotein L, which alters low-
ensity lipoprotein cholesterol (6).
Studies relating the 2 polymorphisms of Hp to heart
isease have been confusing. One of the first studies relating
p to heart disease was performed in 1984 in Belgium (1).
t involved 11,302 subjects and concluded that individuals
omozygous for the Hp1 genotype (Hp1-1) had twice the
ortality rates from CAD over that of other alleles. In
ontrast, subsequent findings by Chapelle et al. (7) claimed
he Hp2 genotype was associated with increased risk for
AD. In 2004, the Framingham study examined Hp
olymorphisms and CHD in a total of 3,283 individuals,
ncluding 443 diabetic subjects and 2,840 nondiabetic sub-
ects (8). Overall, they found no significant cardiac risk
etween the different Hp polymorphisms in the combined
opulation of diabetic and nondiabetic subjects. However,
ubgroup analysis found a higher frequency of the Hp1-1
enotype among diabetic individuals with CHD. Among
he nondiabetic participants, the Hp2 genotype was associ-
ted with increased prevalence of CHD, independent of
onventional risk factors. A study by Holme et al. (9) found
hat low plasma levels of Hp were associated with increased
isk for myocardial infarction. However, despite a large
opulation of 342,125 subjects, of whom nearly 6,500 were
iabetic, there was no relationship between Hp and diabetes.
There is overwhelming data from a variety of studies to
ndicate that 40% to 60% of susceptibility to CAD is genetic
10). Utilization of the high-throughput, single-nucleotide
olymorphism array introduced in 2005 enabled perfor-
ance of unbiased genome-wide association studies
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diseases such as CAD. Before this time, there was more
than a decade of studies using the candidate gene approach,
which claimed that 100 genes were associated with
increased risk for CAD. In subsequent GWAS studies,
none of these genes was confirmed to have an association
with increased risk for CAD (11,12). The candidate gene
approach has thus fallen out of favor, and a new group of
disease-associated genes have been discovered by GWAS,
with confirmation in large independent populations.
GWAS has discovered 1,600 genes associated with in-
creased risk for 160 diseases. Among these, 46 genes were
found to be associated with increased risk for CAD (13).
Despite these discoveries, these genes do not account for
most of the expected heritability of CAD or other diseases
(14,15).
The study by Cahill et al. (16), in this issue of the Journal,
has some very intriguing findings that could transform the
treatment of diabetes. Their overall study conclusion was
that individuals having the Hp2-2 genotype and glycosylated
hemoglobin (HbA1C)6.5% have a 10-fold increased risk of
CHD compared with individuals with at least 1 Hp1 allele
and HbA1C 6.5%. This relative risk ratio makes Hp2-2 a
risk factor comparable to cholesterol in individuals with
HbA1C 6.5%. Patients with the Hp2-2 genotype and
HbA1C 6.5% exhibited no increased risk for CHD.
iabetic subjects treated with metformin to HbA1C 6.5%
with the Hp2-2 genotype also exhibited much less risk for
CHD. A major implication was that good control of
diabetes in individuals with the Hp2-2 genotype would
decrease their risk for ischemic heart disease.
Where have these data associating Hp2 and diabetes been
until now and why now? These findings are startling and
require a careful analysis of the methods used. The overall
approach adopted by Cahill et al. (16) is the candidate gene
approach followed by replication in an independent popu-
lation with subsequent meta-analysis. The initial population
consisted of 407 individuals with myocardial infarction (n
343) or sudden cardiac death (n  64) selected from the
much larger Nurses’ Health Study (NHS) and matched 1:1
with asymptomatic healthy controls, who were also selected
from the NHS. In the NHS cases, there were 25 individuals
with the Hp2-2 genotype and HbA1C 6.5% compared
ith only 2 individuals in the control group with the Hp2-2
enotype and HbA1C 6.5%. This indicates a 10-fold
ncreased relative risk of ischemic heart disease in individ-
als with the Hp2-2 genotype and HbA1C 6.5%. How-
ever, the sample size was too small to provide a definitive
conclusion. The second population selected for replication had
a sample size of 2,070 subjects, all of whom had diabetes but
only 29 cardiac events during follow-up. This is unusual,
because one normally selects an independent population
similar to the original discovery population. In this second
population, there were 18 cardiac events in 452 individuals
with Hp2-2 and HbA1C6.5% versus only 5 cardiac events
in 999 individuals with the Hp1-1 or Hp1-2 genotype andwith HbA1C 6.5%. This finding indicated a 7-fold in-
reased relative risk of cardiac events in those with the
p2-2 genotype and HbA1C 6.5%. A meta-analysis
as performed of these 2 studies, including an additional
ample of 412 individuals (206 cases; 206 controls). The
eta-analysis showed individuals with Hp2-2 and
bA1C levels 6.5% also exhibited a 7-fold increase in
cardiac events.
The increased cardiac risk of the Hp2 genotype has not
been observed in any of the GWAS for either CAD or
diabetes. An international consortium, CARDIoGRAM,
performed a meta-analysis (14) of several GWAS to dis-
cover genetic risk variants for CAD (discovery population of
87,095 and a replication sample of 56,682). There are
several single-nucleotide polymorphisms on the array from
the Hp region, yet none was shown to be associated with
CAD. Practically all of these GWAS included subjects with
diabetes (12). The recent CARDIoGRAMplusC4D, which
had a total population of 194,427, also did not observe any
association of Hp with CAD or diabetes (13). It is note-
worthy that in none of these international studies were the
diabetic subjects stratified into those with HbA1C 6.5%
and those with HbA1C 6.5%. It is reasonable to assume
many of the diabetic subjects would have HbA1C 6.5%.
These results of Cahill et al. (16) are very promising for the
treatment of diabetes but also provocative. The nested case-
control candidate gene approach with such few cases (Hp2
genotype and HbA1C 6.5%) beckons for confirmatory stud-
es before considering any recommendations to alter diabetic
anagement.
Reprint requests and correspondence:Dr. Robert Roberts, Univer-
sity of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario
K1Y 4W7, Canada. E-mail: rroberts@ottawaheart.ca.
REFERENCES
1. De Bacquer D, De Backer G, Langlois M, Delanghe J, Kesteloot H,
Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary
heart disease mortality. Atherosclerosis 2001;157:161–6.
2. Langlois MR, Delanghe JR. Biological and clinical significance of
haptoglobin polymorphism in humans. Clin Chem 1996;42:1589–600.
3. Gutteridge JM. The antioxidant activity of haptoglobin towards
haemoglobin-stimulated lipid peroxidation. Biochim Biophys Acta
1987;917:219–23.
4. Asleh R, Marsh S, Shilkrut M, et al. Genetically determined hetero-
geneity in hemoglobin scavenging and susceptibility to diabetic car-
diovascular disease. Circ Res 2003;92:1193–200.
5. Melamed-Frank M, Lache O, Enav BI, et al. Structure-function
analysis of the antioxidant properties of haptoglobin. Blood 2001;98:
3693–8.
6. Guthrie PA, Rodriguez S, Gaunt TR, Lawlor DA, Smith GD, Day
IN. Complexity of a complex trait locus: HP, HPR, haemoglobin and
cholesterol. Gene 2012;499:8–13.
7. Chapelle JP, Albert A, Smeets JP, Heusghem C, Kulbertus HE. Effect
of the haptoglobin phenotype on the size of a myocardial infarct.
N Engl J Med 1982;307:457–63.
8. Levy AP, Larson MG, Corey D, Lotan R, Vita JA, Benjamin EJ.
Haptoglobin phenotype and prevalent coronary heart disease in the
Framingham offspring cohort. Atherosclerosis 2004;172:361–5.
740 Roberts JACC Vol. 61, No. 7, 2013
Haptoglobin: Is It Evidence Based? February 19, 2013:738–409. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Hapto-
globin and risk of myocardial infarction, stroke, and congestive heart
failure in 342,125 men and women in the Apolipoprotein MOrtality
RISk study (AMORIS). Ann Med 2009;41:522–32.
10. Hunt SC, Gwinn M, Adams TD. Family history assessment: strate-
gies for prevention of cardiovascular disease. Am J Preven Med
2003;24:136–42.
11. Pare G, Serre D, Brisson D, et al. Genetic analysis of 103 candidate
genes for coronary artery disease and associated phenotypes in a
founder population reveals a new association between endothelin-1
and high-density lipoprotein cholesterol. Am J Hum Genet 2007;80:
673–82.
12. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation
of reported genetic risk factors for acute coronary syndrome in a
large-scale replication study. JAMA 2007;297:1551–61. e13. Deloukas P, The CARDIoGRAMplusC4D Consortium, et al. Large-
scale association analysis identifies new risk loci for coronary artery
disease. Nat Genet 2012;45:25–33.
14. Schunkert H, Konig IR, Kathiresan S, et al. Large-scale association
analysis identifies 13 new susceptibility loci for coronary artery disease.
Nat Genet 2011;43:333–8.
15. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of
GWAS discovery. Am J Hum Genet 2012;90:7–24.
16. Cahill L, Levy AP, Chiuve SE, et al. Haptoglobin genotype is a consistent
marker of coronary heart disease risk among individuals with elevated
glycosylated hemoglobin. J Am Coll Cardiol 2013;61:728–37.Key Words: acute myocardial infarction y coronary disease y
pidemiology y genetic association y glycoproteins y 25 genotype.
